- FDA Rare Neurodegenerative Disease Grants Program🔍
- Rare Neurodegenerative Disease Grants Awarded🔍
- RFA|FD|25|001🔍
- Funding Opportunities for Rare Disease Research🔍
- New Request for Applications for FDA Rare Neurodegenerative ...🔍
- Rare Disease Grant Programs🔍
- Office of Orphan Products Development 🔍
- Expired RFA|FD|24|024🔍
New Request for Applications for FDA Rare Neurodegenerative ...
FDA Rare Neurodegenerative Disease Grants Program
Under this program, FDA awards grants and contracts to public and private entities to cover costs of research and development of medical ...
Rare Neurodegenerative Disease Grants Awarded - FDA
In FY 2024, FDA received 15 grant applications and was able to award one new grant to support development of new retinal imaging (imaging the ...
RFA-FD-25-001: Clinical Trials Addressing Unmet Needs of Rare ...
Through the support of collaborative, efficient, and/or innovative clinical trials, FDA expects to increase the number of approved treatments ...
Funding Opportunities for Rare Disease Research - FDA
The purpose of this funding opportunity announcement (FOA) is to fund clinical trials of products evaluating efficacy and/or safety in support ...
New Request for Applications for FDA Rare Neurodegenerative ...
The FDA Rare Neurodegenerative Disease Grant Program was established by the Accelerating Access to Critical Therapies for Amyotrophic Lateral Sclerosis Act.
Rare Disease Grant Programs - FDA
OOPD administers Congressionally mandated grant programs to encourage development of new medical products for rare diseases and conditions.
FDA: Call for applications for the Rare Neurodegenerative Disease ...
The U.S. Food and Drug Administration (FDA) announces a new funding opportunity on “Natural History, Clinical Outcome Assessment, ...
Leave this section blank as it is not used by FDA. Type of Application: For this RFA, “New,” “Resubmission,” “Renewal,” and Revision” applications will be.
Expired RFA-FD-24-024: Natural History, Clinical Outcome ...
With this new funding opportunity announcement (FOA), FDA will continue to address unmet funding needs identified for rare neurodegenerative ...
FDA Rare Neurodegenerative Disease Grant Program
Request for Fiscal Year 2023 Grant Funding Concepts. Congress, through the ... In this new program, grants or contracts will be awarded to public and ...
View Grant Opportunity Forecast - Search Results Detail | Grants.gov
Opportunity Number: FOR-FD-25-001 ; Opportunity Title: Clinical Trials Addressing Unmet Needs of Rare Neurodegenerative Diseases (R01) Clinical ...
Resources for Applicants and Grantees | FDA
The FDA's rare disease grant programs offer funding opportunities for rare disease research. Applicants may find the resources below useful when preparing ...
FDA Updates Information on Rare Neurodegenerative Disease ...
Under this program, grants and contracts are awarded to public and private entities to cover costs of research and development of medical ...
U.S. FDA on X: "FDA invites applications for the FDA Rare ...
FDA invites applications for the FDA Rare Neurodegenerative Disease ... Apply by Oct. 22. https://t.co/DgqZbQ5wLB.
Accelerating Access to Critical Therapies for ALS Act - FDA
Under CDER's eligibility criteria, the product must be intended to treat rare neurodegenerative conditions, including those of rare genetic ...
Clinical Trials Addressing Unmet Needs of Rare Neurodegenerative ...
On 8/23/24 Food and Drug Administration issued RFA-FD-25-001 for Clinical Trials Addressing Unmet Needs of Rare Neurodegenerative Diseases (R01) Clinical ...
FDA Approves Second Drug to Treat Rare Neurodegenerative ...
AstraZeneca and Daiichi Sankyo have submitted a new biologics license application (BLA) for accelerated approval for datopotamab deruxtecan ...
FNIH Biomarkers Consortium Receives FDA Acceptance for Letter of ...
FNIH Biomarkers Consortium Receives FDA Acceptance for Letter of Intent to Qualify Neurofilament as Biomarker of Rare Neurodegenerative Disease.
Support for Clinical Trials Advancing Rare Disease Therapeutics ...
FDA intends to issue a letter to notify each sponsor of FDA's decision on sponsor requests to participate within 90 days of the application ...
Getting START'ed: New FDA programs aim to advance drugs to treat ...
For an application to CDER, the product must be intended to treat rare neurodegenerative conditions (including those of rare genetic metabolic ...